At the recent AAPS National Biotech Conference 2025, pharmaphorum editor-in-chief Jonah Comstock caught up with Dr Dhaval Shah, a professor of pharmaceutical sciences at the University of Buffalo and ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...

The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...

The demise of the pharmaceutical sales representative has been greatly exaggerated over the years. But in the wake of the COVID-19 pandemic, there is an even greater need to re-examine the rep's role.

In recent years, pharma companies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time between ...

To add to the relevance of this point, not only are HCPs expecting them, but we know that they work. In fact, as IQVIA’s ChannelDynamics shows, the impact of remote detailing on HCPs reported ...

Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple myeloma, and told delegates at ASH yesterday why its talquetamab ...

Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder. Rejoyn (formerly CT-152), a ...